Erschienen in:
01.08.2008 | Adis Drug Profile
Lutropin Alfa
A Viewpoint by Giuseppe De Placido, Roberto Clarizia and Carlo Alviggi
verfasst von:
Giuseppe De Placido, Roberto Clarizia, Carlo Alviggi
Erschienen in:
Drugs
|
Ausgabe 11/2008
Einloggen, um Zugang zu erhalten
Excerpt
Recombinant-DNA technology has provided us with qualitatively and quantitatively consistent preparations of gonadotropins. Thus, we can treat patients separately with recombinant human follicle stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) according to the specific indication. Hypogonadotropic hypogonadism is the main indication where r-hLH is used along with r-hFSH. This clinical approach is consistent with the classical ‘two cell–two gonadotropins’ theory. …